SMTL ID : 5tq3.1 (1 other biounit)

Design and Synthesis of a pan-JAK kinase inhibitor clinical candidate (PF-06263276) suitable for the treatment of inflammatory diseases of the lungs and skin

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 2.69 Å

Oligo State

monomer

Ligands

1 x 7GZ: 4-[3-(1H-benzimidazol-2-yl)-1H-indazol-6-yl]-3-ethylphenol(Non-covalent)

7GZ.1: 17 residues within 4Å: Chain A: L.27, A.52, K.54, E.70, L.74, V.83, L.99, M.101, E.102, Y.103, L.104, P.105, G.107, L.155, G.165, D.166, F.167 10 PLIP interactions: 10 interactions with chain A Hydrophobic interactions: A:L.27, A:K.54, A:V.83, A:L.99, A:Y.103, A:L.155 Hydrogen bonds: A:E.70, A:E.102, A:L.104, A:F.167

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Jones, P. et al., Design and Synthesis of a Pan-Janus Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin. J. Med. Chem. (2017)

Release Date

2017-01-11

Peptides

Tyrosine-protein kinase JAK2: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

Tyrosine-protein kinase JAK2

Related Entries With Identical Sequence